Search: id:"swepub:oai:lup.lub.lu.se:19aabc30-bc7c-4935-8082-7d7020ef7825" > A retrospective stu...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03496naa a2200373 4500 | |
001 | oai:lup.lub.lu.se:19aabc30-bc7c-4935-8082-7d7020ef7825 | |
003 | SwePub | |
008 | 160404s2010 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/16447552 URI |
024 | 7 | a https://doi.org/10.1097/MBC.0b013e32833c9ab92 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Berntorp, Eriku Lund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups4 aut0 (Swepub:lu)medf-ebe |
245 | 1 0 | a A retrospective study of Octaplex in the treatment of bleeding in patients with haemophilia A complicated by inhibitors. |
264 | 1 | c 2010 |
520 | a The nonactivated prothrombin complex concentrate (PCC) Octaplex (Octapharma PPGmbH, Vienna, Austria) has been used successfully for the treatment of congenital and acquired coagulation factor deficiencies and associated bleeding. The aims of this study were to assess retrospectively whether Octaplex is an effective treatment option for haemophilia A patients with high-titre inhibitors of factor VIII (FVIII) and to investigate the impact of Octaplex on thrombin generation in vitro and ex vivo. Retrospective data were collected from 15 haemophilia A patients with FVIII inhibitors who had been treated with Octaplex. Mild bleeds were treated for a median of 1 day with a median dose of 77 IU/kg and moderate bleeds for 3 days with 57 IU/kg. The physician's overall satisfaction with Octaplex, taking into account efficacy, safety and cost in comparison with other treatment options, was assessed for each bleed. The overall rating was good, very good or excellent for 29 of 41 (71%) bleeds. No adverse drug reactions were reported. In in-vitro studies of thrombin generation with normal plasma samples, experimental inhibition of FVIII activity prolonged the lag phase, diminished the peak thrombin concentration and decreased the area under the concentration-time curve, as expected. Marked improvement in thrombin generation parameters was achieved by adding 0.5-3 IU factor IX/ml PCC into the samples. The same held true when using plasma samples from haemophilia A patients with FVIII inhibitors. These results demonstrate that Octaplex overcomes inhibition of FVIII in in-vitro and ex-vivo assays of thrombin generation, and that Octaplex is an effective treatment option for haemophilia A patients with FVIII inhibitors. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
700 | 1 | a Figueiredo, Sandra4 aut |
700 | 1 | a Futema, Lucimara4 aut |
700 | 1 | a Pock, Katharina4 aut |
700 | 1 | a Knaub, Sigurd4 aut |
700 | 1 | a Walter, Olaf4 aut |
700 | 1 | a Trawnicek, Laurenz4 aut |
700 | 1 | a Römisch, Jürgen4 aut |
710 | 2 | a Klinisk koagulationsmedicin, Malmöb Forskargrupper vid Lunds universitet4 org |
773 | 0 | t Blood Coagulation and Fibrinolysisg 21, s. 577-583q 21<577-583x 1473-5733 |
856 | 4 | u http://www.ncbi.nlm.nih.gov/pubmed/20644466?dopt=Abstracty FULLTEXT |
856 | 4 | u http://dx.doi.org/10.1097/MBC.0b013e32833c9ab9y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/1644755 |
856 | 4 8 | u https://doi.org/10.1097/MBC.0b013e32833c9ab9 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.